SAN DIEGO—The 2017 ACR/ARHP Annual Meeting, Nov. 3–8, presented opportunities to highlight its 2017 legislative advocacy victories, some of which were resolved just weeks before the conference began, as well as issues that are still outstanding. In the session, Legislative & Regulatory Update 2017, Angus Worthing, MD, chair of the ACR’s Government Advocacy Committee and…
Systemic lupus erythematosus (SLE) is an autoimmune-mediated rheumatic disease characterized by multisystem involvement that can cause significant morbidity and mortality. Acute disseminated encephalomyelitis (ADEM) is a rare, fulminant, autoimmune-mediated, demyelinating disease involving the white matter of the central nervous system (CNS), and is considered a manifestation of neuropsychiatric lupus. Few reported cases involve SLE and…
During the 2017 ACR/ARHP Annual Meeting, advances in biosimilar treatments were abuzz. However, many speakers noted that the presence of biosimilars on the market has not yet resulted in greater access to treatment and lower drug pricing in the U.S…
SAN DIEGO—After sifting through the nitty-gritty of the rheumatic disease literature on basic science, Richard Pope, MD—professor of medicine specializing in rheumatology at Northwestern University Feinberg School of Medicine—underscored several findings he thought stood out from the pack in his Year in Review talk at the 2017 ACR/ARHP Annual Meeting. He reviewed findings from November…
SAN DIEGO—At the 2017 ACR/ARHP Annual Meeting in San Diego last month, the ACR and the ARHP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the ACR winners about their individual contributions to advancing rheumatology. In coming issues, we…
In a Year in Review session at the 2017 ACR/ARHP Annual Meeting, Daniel Solomon, MD, MPH, highlighted the latest and most intriguing aspects of clinical research on rheumatic diseases from 2017. His discussion touched on medical therapy, genetics, the effects of bariatric surgery and diet, cancer risk and more…
SAN DIEGO—Should patients with rheumatic diseases switch from a biologic to its biosimilar? At the 2017 ACR/ARHP Annual Meeting’s Great Debate, held Nov. 5, two rheumatologists argued whether to switch or stay put based on safety, efficacy and potential cost savings. First to the podium to make the case for switching, Jonathan Kay, MD, tweaked…
During the ACR/ARHP Annual Meeting, Richard Pope, MD, highlighted some of the top scientific literature on rheumatic disease from 2017. The review session discussed research on the effects of microglia on the central nervous system of SLE patients, the role of adenosine in osteoarthritis and more…
SAN DIEGO—The 2017 ACR/ARHP Annual Meeting kicked off on Nov. 4 with a rousing presentation by Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases (NIAID). A terrorist attack on U.S. soil, hurricane, cyberattack and pandemic were the four scenarios played out in late 2016, when NIAID conducted a tabletop…
Efficiently meeting the needs of people with rheumatic disease requires the expertise of a team of health professionals. During their formal education, health professionals acquire the knowledge, skills and attitudes that prepare them to best contribute to a healthcare team. Maintaining and expanding that knowledge happens during continuing education and post-graduate programs, which ensure lifelong…